Harmony Biosciences Holdings, Inc.: management transactions · United States · SEC (Form 4)

About Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. is a U.S.-based pharmaceutical company listed on the NASDAQ in the United States, with corporate headquarters in Plymouth Meeting, Pennsylvania. The company was founded in July 2017 as Harmony Biosciences II, LLC, converted to Harmony Biosciences II, Inc. in September 2017, and adopted its current name in February 2020. Its strategic focus is the development and commercialization of innovative therapies for patients with rare neurological disorders and other neurological diseases that still have significant unmet medical need. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926018859/hrmy-20251231x10k.htm)) From an operating standpoint, Harmony remains highly concentrated around WAKIX (pitolisant), its only commercially approved and marketed product to date. WAKIX is the company’s flagship franchise and the principal driver of revenue, making the investment case closely tied to the product’s continued penetration in narcolepsy. Harmony’s latest filings and investor materials also emphasize a broader pipeline strategy, including business development and licensing activity aimed at sleep/wake disorders, epilepsy, rare/orphan CNS assets, and adjacent central nervous system opportunities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926018859/hrmy-20251231x10k.htm)) Competitive positioning is that of a focused specialty biopharma player rather than a diversified large-cap pharmaceutical company. That specialization can be an advantage in rare neurological disease, where deep commercial execution, physician education, payer access, and patient support are critical. At the same time, the company is exposed to concentration risk because its historical and current financial profile is heavily dependent on WAKIX. Management explicitly notes the importance of sustained sales growth, intellectual property protection, market access, and successful development of additional products beyond WAKIX. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926018859/hrmy-20251231x10k.htm)) Recent developments suggest a still-strong commercial trajectory. In Q1 2026, Harmony reported net product revenue of $215.4 million for WAKIX, up 17% year over year, and reiterated full-year 2026 net revenue guidance of more than $1 billion. The company also reported $870.5 million in cash, cash equivalents and investments at March 31, 2026, and announced executive leadership changes, including a new COO and CFO. In parallel, Harmony highlighted open-label extension data from its Phase 3 ARGUS program, reinforcing the company’s intent to broaden its development portfolio and create longer-dated growth drivers. ([ir.harmonybiosciences.com](https://ir.harmonybiosciences.com/news-releases/news-release-details/harmony-biosciences-reports-q1-financial-results-and-confirms)) For French-speaking investors, Harmony Biosciences is therefore best viewed as a niche U.S. neurology and rare-disease pharmaceutical company on NASDAQ, with a commercial base centered in the United States and a pipeline strategy designed to reduce its dependence on a single asset over time. Its profile combines solid current cash generation, high exposure to WAKIX, and optionality from new licensing and development programs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001802665/000110465926018859/hrmy-20251231x10k.htm))